Search peptides, terms, sources/
Glossary

Marketing Authorisation

The formal approval a medicine must hold from a regulator, such as the MHRA in the UK, before it can lawfully be sold or supplied for a stated medical use. A peptide without UK marketing authorisation is not a licensed medicine in the UK, whatever its status may be in another country, which is why this site states each peptide’s marketing-authorisation status individually rather than assuming one status applies to the whole catalogue.

Peptides where this matters

  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Tirzepatide

    Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • TesamorelinTH9507

    Not licensed in the UK. Growth-hormone-releasing hormone analogue studied for visceral fat in HIV-associated lipodystrophy, in randomised trials.

    Growth hormone axisHuman trialsEvidence reviewed
    StrongNot licensed in the UK

All glossary terms

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.